Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection – Scotland, 2012-2013

Rajendran, R., Sherry, L., Nile, C. , Sherriff, A. , Johnson, E., Hanson, M., Williams, C., Munro, C., Jones, B. and Ramage, G. (2016) Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection – Scotland, 2012-2013. Clinical Microbiology and Infection, 22(1), pp. 87-93. (doi:10.1016/j.cmi.2015.09.018) (PMID:26432192)

Rajendran, R., Sherry, L., Nile, C. , Sherriff, A. , Johnson, E., Hanson, M., Williams, C., Munro, C., Jones, B. and Ramage, G. (2016) Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection – Scotland, 2012-2013. Clinical Microbiology and Infection, 22(1), pp. 87-93. (doi:10.1016/j.cmi.2015.09.018) (PMID:26432192)

[img]
Preview
Text
110789.pdf - Published Version
Available under License Creative Commons Attribution.

502kB

Abstract

Bloodstream infections caused by Candida species remain a significant cause of morbidity and mortality in hospitalised patients. Biofilm formation by Candida species is an important virulence factor for disease pathogenesis. A prospective analysis of patients with Candida bloodstream infection (n=217) in Scotland (2012/13) was performed to assess the risk factors associated with patient mortality; in particular the impact of biofilm formation. Candida bloodstream isolates (n=280) and clinical records for 157 patients were collected through 11 different health boards across Scotland. Biofilm formation by clinical isolates was assessed in vitro by standard biomass assays. The role of biofilm phenotype on treatment efficacy was also evaluated in vitro by treating preformed biofilms by fixed concentrations of different classes of antifungals. Out of 134 available patient mortality data, the 30-day candidaemia case mortality was 41%, with predisposing factors including patient age and catheter removal. Multivariate Cox’s regression survival analysis with 42 patients showed significantly higher mortality with C. albicans infection compared to C. glabrata. Biofilm-forming ability was significantly associated with C. albicans mortality (n=34 patients). Finally, in-vitro antifungal sensitivity testing showed that LBF and HBF were differentially affected by azoles and echinocandins, but not polyenes. This study provides further evidence of the biofilm phenotype represents a significant clinical entity, and that isolates with this phenotype differentially respond to antifungal therapy based on in vitro evidence. Collectively, these findings highlight that a greater clinical understanding is required with respect to Candida biofilm infections, and the implications of isolate heterogeneity.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Sherriff, Dr Andrea and Ramage, Professor Gordon and Rajendran, Dr Ranjith and Williams, Dr Craig and Nile, Dr Christopher and Sherry, Dr Leighann and Jones, Dr Brian
Authors: Rajendran, R., Sherry, L., Nile, C., Sherriff, A., Johnson, E., Hanson, M., Williams, C., Munro, C., Jones, B., and Ramage, G.
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing > Dental School
Journal Name:Clinical Microbiology and Infection
Publisher:Elsevier
ISSN:1198-743X
ISSN (Online):1469-0691
Copyright Holders:Copyright © 2015 The Authors
First Published:First published in Clinical Microbiology and Infection 2015
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record